Rapid Dose Therapeutics Corp. (RDTCF)
USD 0.18
(2150.0%)
USD 0.18
(2150.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 5.04 Million CAD | 2.57% |
| 2023 | 4.91 Million CAD | 74.56% |
| 2022 | 2.81 Million CAD | -47.97% |
| 2021 | 5.41 Million CAD | 22.0% |
| 2020 | 4.43 Million CAD | 126.92% |
| 2019 | 1.95 Million CAD | 6453.81% |
| 2018 | 29.83 Thousand CAD | -20.96% |
| 2017 | 37.75 Thousand CAD | 60.29% |
| 2016 | 23.55 Thousand CAD | -17.92% |
| 2015 | 28.69 Thousand CAD | -2.3% |
| 2014 | 29.36 Thousand CAD | -32.16% |
| 2013 | 43.29 Thousand CAD | -18.78% |
| 2012 | 53.3 Thousand CAD | 348.57% |
| 2011 | 11.88 Thousand CAD | -50.64% |
| 2010 | 24.07 Thousand CAD | 381.52% |
| 2009 | 5000.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 5.04 Million CAD | -22.77% |
| 2024 FY | 5.04 Million CAD | 2.57% |
| 2024 Q3 | 6.52 Million CAD | 10.01% |
| 2024 Q1 | 5.31 Million CAD | 8.01% |
| 2024 Q2 | 5.93 Million CAD | 11.77% |
| 2023 FY | 4.91 Million CAD | 74.56% |
| 2023 Q4 | 4.91 Million CAD | 18.12% |
| 2023 Q3 | 4.16 Million CAD | 9.85% |
| 2023 Q2 | 3.78 Million CAD | 16.23% |
| 2023 Q1 | 3.26 Million CAD | 15.76% |
| 2022 Q3 | 2.32 Million CAD | -13.63% |
| 2022 Q4 | 2.81 Million CAD | 21.06% |
| 2022 FY | 2.81 Million CAD | -47.97% |
| 2022 Q1 | 3.05 Million CAD | -43.64% |
| 2022 Q2 | 2.69 Million CAD | -11.71% |
| 2021 Q2 | 5.15 Million CAD | 10.99% |
| 2021 FY | 5.41 Million CAD | 22.0% |
| 2021 Q4 | 5.41 Million CAD | -4.84% |
| 2021 Q3 | 5.68 Million CAD | 10.35% |
| 2021 Q1 | 4.64 Million CAD | 4.68% |
| 2020 Q3 | 3.93 Million CAD | 131.8% |
| 2020 Q1 | 1.65 Million CAD | -15.44% |
| 2020 Q2 | 1.69 Million CAD | 2.67% |
| 2020 Q4 | 4.43 Million CAD | 12.75% |
| 2020 FY | 4.43 Million CAD | 126.92% |
| 2019 FY | 1.95 Million CAD | 6453.81% |
| 2019 Q1 | 114.61 Thousand CAD | -18.03% |
| 2019 Q3 | 496.74 Thousand CAD | 807.6% |
| 2019 Q4 | 1.95 Million CAD | 293.68% |
| 2019 Q2 | 54.73 Thousand CAD | -52.25% |
| 2018 Q4 | 139.83 Thousand CAD | 316.25% |
| 2018 Q3 | 33.59 Thousand CAD | 12.58% |
| 2018 Q2 | 29.83 Thousand CAD | 68.86% |
| 2018 Q1 | 17.67 Thousand CAD | 13.5% |
| 2018 FY | 29.83 Thousand CAD | -20.96% |
| 2017 Q3 | 36.9 Thousand CAD | -2.25% |
| 2017 Q4 | 15.56 Thousand CAD | -57.81% |
| 2017 FY | 37.75 Thousand CAD | 60.29% |
| 2017 Q1 | 23.57 Thousand CAD | 3.99% |
| 2017 Q2 | 37.75 Thousand CAD | 60.15% |
| 2016 Q1 | 3767.00 CAD | -28.6% |
| 2016 FY | 23.55 Thousand CAD | -17.92% |
| 2016 Q3 | 21.3 Thousand CAD | -9.52% |
| 2016 Q2 | 23.55 Thousand CAD | 525.19% |
| 2016 Q4 | 22.66 Thousand CAD | 6.38% |
| 2015 FY | 28.69 Thousand CAD | -2.3% |
| 2015 Q1 | 76.04 Thousand CAD | 14.55% |
| 2015 Q2 | 28.69 Thousand CAD | -62.27% |
| 2015 Q4 | 5276.00 CAD | -49.38% |
| 2015 Q3 | 10.42 Thousand CAD | -63.68% |
| 2014 Q4 | 66.39 Thousand CAD | 48.98% |
| 2014 FY | 29.36 Thousand CAD | -32.16% |
| 2014 Q2 | 29.36 Thousand CAD | -5.11% |
| 2014 Q1 | 30.94 Thousand CAD | 8.45% |
| 2014 Q3 | 44.56 Thousand CAD | 51.74% |
| 2013 Q2 | 43.29 Thousand CAD | 63.73% |
| 2013 Q4 | 28.53 Thousand CAD | -19.81% |
| 2013 FY | 43.29 Thousand CAD | -18.78% |
| 2013 Q1 | 26.44 Thousand CAD | -35.31% |
| 2013 Q3 | 35.58 Thousand CAD | -17.8% |
| 2012 FY | 53.3 Thousand CAD | 348.57% |
| 2012 Q2 | 53.3 Thousand CAD | 0.0% |
| 2012 Q1 | - CAD | -100.0% |
| 2012 Q3 | 34.84 Thousand CAD | -34.62% |
| 2012 Q4 | 40.87 Thousand CAD | 17.29% |
| 2011 Q3 | 18.66 Thousand CAD | 57.06% |
| 2011 Q1 | 2859.00 CAD | -63.19% |
| 2011 Q2 | 11.88 Thousand CAD | 315.63% |
| 2011 Q4 | 1832.00 CAD | -90.18% |
| 2011 FY | 11.88 Thousand CAD | -50.64% |
| 2010 FY | 24.07 Thousand CAD | 381.52% |
| 2010 Q3 | 6419.00 CAD | -73.34% |
| 2010 Q4 | 7767.00 CAD | 21.0% |
| 2010 Q2 | 24.07 Thousand CAD | 0.0% |
| 2009 FY | 5000.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -501.279% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -100.416% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 2.0% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 93.041% |
| GB Sciences, Inc. | 5.41 Million USD | 6.912% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -37.596% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -221.961% |
| Skye Bioscience, Inc. | 14.07 Million USD | 64.163% |
| Zenith Capital Corp. | 27.56 Thousand USD | -18192.709% |
| Agentix Corp. | 2.51 Million USD | -100.877% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 46.723% |
| Biomind Labs Inc. | 1.49 Million USD | -236.519% |
| ContraFect Corporation | 32.53 Million USD | 84.498% |
| CSL Limited | 18.62 Billion USD | 99.973% |
| CytoDyn Inc. | 127.89 Million USD | 96.057% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -251.716% |
| Neon Bloom, Inc. | 1.22 Million USD | -311.276% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 93.269% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -11183.151% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -30.942% |
| Regen BioPharma, Inc. | 5.45 Million USD | 7.595% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 91.454% |
| SQZ Biotechnologies Company | 50.03 Million USD | 89.922% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -150.885% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 90.539% |
| Intellipharmaceutics International Inc. | 12 Million USD | 58.005% |
| Mesoblast Limited | 188.44 Million USD | 97.324% |
| Marizyme, Inc. | 26.67 Million USD | 81.095% |
| Genus plc | 485 Million USD | 98.96% |
| Pharming Group N.V. | 244.07 Million USD | 97.934% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -32.714% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -31.755% |
| IMV Inc. | 37.93 Million USD | 86.705% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 57.183% |
| MultiCell Technologies, Inc. | 1617.67 USD | -311651.902% |
| ONE Bio Corp. | 27.49 Million USD | 81.659% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 93.486% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.919% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 44.227% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 72.597% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3449.116% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2407.566% |
| Alpha Cognition Inc. | 7.16 Million USD | 29.612% |
| Enzolytics Inc. | 365.26 Million USD | 98.619% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.867% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -194.231% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 79.62% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.62% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 47.369% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1096.276% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -35.048% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -640.726% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -85.98% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 13.684% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -154.535% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 1.07 Million USD | -367.285% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -7435.025% |
| EV Biologics, Inc. | 2.11 Million USD | -138.437% |
| Q BioMed Inc. | 8.13 Million USD | 37.991% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 89.967% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.752% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 68.292% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 12.23% |
| HST Global, Inc. | 593.59 Thousand USD | -749.592% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -18283.396% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -300.504% |
| Halberd Corporation | 728.71 Thousand USD | -592.052% |
| Resverlogix Corp. | 67.39 Million USD | 92.517% |
| Cell Source, Inc. | 15.8 Million USD | 68.095% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 57.632% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 3.99 Million USD | -26.275% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2013.15% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | 35.844% |
| Kadimastem Ltd | 3.5 Million USD | -43.889% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -145.818% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -985.244% |
| LadRx Corporation | 2.2 Million USD | -129.178% |
| Regen BioPharma, Inc. | 5.45 Million USD | 7.595% |
| Affymax, Inc. | 8.87 Million USD | 43.151% |
| Itoco Inc. | 1.65 Million USD | -205.061% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 16.629% |
| Mobile Lads Corp. | 1.31 Million USD | -283.946% |
| International Stem Cell Corporation | 5.27 Million USD | 4.432% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.24 Million USD | -55.197% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -11965.162% |
| Qrons Inc. | 1.48 Million USD | -238.757% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 54.341% |
| SYBLEU INC | 681.41 Thousand USD | -640.097% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -523.535% |
| Rebus Holdings, Inc. | 5.24 Million USD | 3.794% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 17.352% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -705.856% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -9.226% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 87.699% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 77.35% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -148.995% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 7.939% |
| Neutra Corp. | 973.52 Thousand USD | -418.024% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 82.619% |
| PureTech Health plc | 125.58 Million USD | 95.984% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -34.228% |
| IXICO plc | 1.9 Million USD | -165.386% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 75.434% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 95.119% |
| CSL Limited | 18.62 Billion USD | 99.973% |
| Cellectis S.A. | 249.36 Million USD | 97.978% |